The FDA approved pembrolizumab (Keytruda, Merck) for the treatment of patients with microsatellite instability?high (MSI-H) or mismatch repair?deficient (dMMR) advanced endometrial carcinoma who have had prior systemic therapy and are not candidates for curative surgery or radiation therapy.
The approval was based on new data from the multicenter, nonrandomized, open-label, multiple-cohort KEYNOTE-158 trial—specifically 90 patients with unresectable or metastatic MSI-H or dMMR endometrial